Is VCNX or FNCH more profitable?

Vaccinex's return on equity of 0.00% beat Finch Therapeutics Group's return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Finch Therapeutics Group N/A -69.14% -26.92%

Do analysts prefer VCNX or CABR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Caring Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VCNX or CABR more profitable?

Vaccinex's return on equity of 0.00% beat Caring Brands' return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Caring Brands N/A -1,153.12% -322.63%

Do analysts recommend PBM or VCNX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PBM or VCNX more profitable?

Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Vaccinex N/A N/A -383.58%

Do analysts rate VCNX or PSTV?

Plus Therapeutics has a consensus target price of $51.75, suggesting a potential upside of 2,759.12%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is VCNX or PSTV more profitable?

Vaccinex has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Vaccinex's return on equity of 0.00% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Plus Therapeutics -230.24% -198.48% -73.13%

Do analysts rate VCNX or KPRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VCNX or KPRX more profitable?

Vaccinex's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Kiora Pharmaceuticals N/A -63.38% -44.33%

Does the media refer more to VCNX or KPRX?

In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Vaccinex. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 1 mentions for Vaccinex. Kiora Pharmaceuticals' average media sentiment score of 0.84 beat Vaccinex's score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaccinex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kiora Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vaccinex (VCNX) Competitors

$1.05 -0.07 (-6.25%)

As of 11:28 AM Eastern

Compare

VCNX vs. FNCH, CABR, PBM, PSTV, and KPRX

Should you buy Vaccinex stock or one of its competitors? Vaccinex's main competitors and comparable companies include Finch Therapeutics Group (FNCH), Caring Brands (CABR), Psyence Biomedical (PBM), Plus Therapeutics (PSTV), and Kiora Pharmaceuticals (KPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Vaccinex compare to Finch Therapeutics Group?

Vaccinex (NASDAQ:VCNX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Vaccinex has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	7.04	-$20.25M	-$48.27	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vaccinex's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Vaccinex has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

In the previous week, Vaccinex had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for Vaccinex and 0 mentions for Finch Therapeutics Group. Vaccinex's average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
Finch Therapeutics Group	Neutral

Summary

Vaccinex beats Finch Therapeutics Group on 7 of the 10 factors compared between the two stocks.

How does Vaccinex compare to Caring Brands?

Vaccinex (NASDAQ:VCNX) and Caring Brands (NASDAQ:CABR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Caring Brands had 1 more articles in the media than Vaccinex. MarketBeat recorded 2 mentions for Caring Brands and 1 mentions for Vaccinex. Caring Brands' average media sentiment score of 1.44 beat Vaccinex's score of 0.00 indicating that Caring Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Vaccinex	Neutral
Caring Brands	Positive

Caring Brands has lower revenue, but higher earnings than Vaccinex. Caring Brands is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	7.04	-$20.25M	-$48.27	N/A
Caring Brands	N/A	N/A	-$6.28M	-$0.74	N/A

50.1% of Vaccinex shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 14.6% of Caring Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vaccinex's return on equity of 0.00% beat Caring Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Caring Brands	N/A	-1,153.12%	-322.63%

Summary

Caring Brands beats Vaccinex on 6 of the 10 factors compared between the two stocks.

How does Vaccinex compare to Psyence Biomedical?

Psyence Biomedical (NASDAQ:PBM) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Psyence Biomedical has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Psyence Biomedical has higher earnings, but lower revenue than Vaccinex. Vaccinex is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.18
Vaccinex	$388K	7.04	-$20.25M	-$48.27	N/A

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Vaccinex	N/A	N/A	-383.58%

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by insiders. Comparatively, 51.5% of Vaccinex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Psyence Biomedical had 1 more articles in the media than Vaccinex. MarketBeat recorded 2 mentions for Psyence Biomedical and 1 mentions for Vaccinex. Psyence Biomedical's average media sentiment score of 1.39 beat Vaccinex's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Psyence Biomedical	Positive
Vaccinex	Neutral

Summary

Psyence Biomedical beats Vaccinex on 8 of the 10 factors compared between the two stocks.

How does Vaccinex compare to Plus Therapeutics?

Vaccinex (NASDAQ:VCNX) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Plus Therapeutics has a consensus target price of $51.75, suggesting a potential upside of 2,759.12%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Vaccinex has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Vaccinex's return on equity of 0.00% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

In the previous week, Vaccinex had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 1 mentions for Vaccinex and 0 mentions for Plus Therapeutics. Vaccinex's average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
Plus Therapeutics	Neutral

Vaccinex has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	7.04	-$20.25M	-$48.27	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Summary

Vaccinex beats Plus Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Vaccinex compare to Kiora Pharmaceuticals?

Vaccinex (NASDAQ:VCNX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Kiora Pharmaceuticals has higher revenue and earnings than Vaccinex. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	7.04	-$20.25M	-$48.27	N/A
Kiora Pharmaceuticals	$16.02M	0.68	-$10.84M	-$2.51	N/A

Vaccinex has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.22, meaning that its stock price is 122% less volatile than the broader market.

Vaccinex's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Vaccinex. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 1 mentions for Vaccinex. Kiora Pharmaceuticals' average media sentiment score of 0.84 beat Vaccinex's score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaccinex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiora Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Kiora Pharmaceuticals beats Vaccinex on 8 of the 13 factors compared between the two stocks.

Get Vaccinex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCNX vs. The Competition

Export

Metric	Vaccinex	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.73M	$12.41B	$7.28B	$12.93B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-0.02	807.82	275.40	25.27
Price / Sales	7.04	748.52	562.90	78.90
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	-0.41	9.20	10.55	5.93
Net Income	-$20.25M	$2.84B	$3.50B	$380.91M
7 Day Performance	-8.70%	-4.07%	-3.94%	-4.21%
1 Month Performance	-0.94%	-8.13%	-8.33%	-7.05%
1 Year Performance	100.31%	-5.87%	2.44%	-4.87%

Vaccinex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCNX Vaccinex	N/A	$1.05 -6.3%	N/A	+100.3%	$2.73M	$388K	N/A	25	Gap Down
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
CABR Caring Brands	0.8527 of 5 stars	$1.13 -7.4%	N/A	N/A	$11.72M	N/A	N/A	3	Positive News Short Interest Decrease Gap Down
PBM Psyence Biomedical	1.584 of 5 stars	$5.11 +4.7%	N/A	-79.6%	$11.70M	N/A	0.20	12	Short Interest Decrease
PSTV Plus Therapeutics	N/A	$1.64 +2.8%	$51.75 +3,065.1%	-89.3%	$11.26M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCNX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaccinex (VCNX) Competitors

VCNX vs. FNCH, CABR, PBM, PSTV, and KPRX

How does Vaccinex compare to Finch Therapeutics Group?

Summary

How does Vaccinex compare to Caring Brands?

Summary

How does Vaccinex compare to Psyence Biomedical?

Summary

How does Vaccinex compare to Plus Therapeutics?

Summary

How does Vaccinex compare to Kiora Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaccinex (VCNX) Competitors

VCNX vs. FNCH, CABR, PBM, PSTV, and KPRX

How does Vaccinex compare to Finch Therapeutics Group?

Which has better earnings and valuation, VCNX or FNCH?

Do insiders and institutionals believe in VCNX or FNCH?

Is VCNX or FNCH more profitable?

Which has more risk and volatility, VCNX or FNCH?

Does the media refer more to VCNX or FNCH?

Summary

How does Vaccinex compare to Caring Brands?

Do analysts prefer VCNX or CABR?

Does the media refer more to VCNX or CABR?

Which has stronger valuation & earnings, VCNX or CABR?

Do insiders and institutionals have more ownership in VCNX or CABR?

Is VCNX or CABR more profitable?

Summary

How does Vaccinex compare to Psyence Biomedical?

Do analysts recommend PBM or VCNX?

Which has more volatility & risk, PBM or VCNX?

Which has preferable earnings and valuation, PBM or VCNX?

Is PBM or VCNX more profitable?

Do institutionals and insiders have more ownership in PBM or VCNX?

Does the media favor PBM or VCNX?

Summary

How does Vaccinex compare to Plus Therapeutics?

Do institutionals & insiders hold more shares of VCNX or PSTV?

Do analysts rate VCNX or PSTV?

Is VCNX or PSTV more profitable?

Which has more risk & volatility, VCNX or PSTV?

Does the media refer more to VCNX or PSTV?

Which has better valuation & earnings, VCNX or PSTV?

Summary

How does Vaccinex compare to Kiora Pharmaceuticals?

Which has preferable earnings & valuation, VCNX or KPRX?

Which has more volatility and risk, VCNX or KPRX?

Is VCNX or KPRX more profitable?

Does the media refer more to VCNX or KPRX?

Do analysts rate VCNX or KPRX?

Do insiders and institutionals hold more shares of VCNX or KPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools